Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Sanofi Genzyme.

Optimizing Outcomes in Cold Agglutinin Disease: Exploring the Impact of Rapid Diagnosis and Emerging Therapeutic Agents

Release Date: July 14, 2021
Expiration Date: July 14, 2022

Activity Overview

Cold agglutinin disease (CAD) has a significant impact on patients’ quality of life. Historically, the limited availability of treatment options has hindered management of CAD. However, the treatment landscape is shifting as novel therapies are developed based on improved understanding of the role of the complement system in the pathogenesis of CAD. Health care professionals require a strong foundation of knowledge in the efficacy, safety, and role of both available and emerging therapies for CAD to improve the outcomes in this patient population.

This program features experts presenting important topics on CAD, including the burden of disease and the impact of CAD on patient quality of life, as well as the role of the complement system in CAD. The program also includes expert review of current and emerging data surrounding strategies for rapid and accurate diagnosis, current management approaches and the potential of emerging treatments.

This educational activity is an archive of the live virtual presentation held on June 10, 2021.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward hematologists and hematologist-oncologists who treat patients with cold agglutinin disease. Fellows, nurses, nurse practitioners, and other health care professionals interested in the management of patients with cold agglutinin disease are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the clinical burden of cold agglutinin disease.
  • Explain how the complement system is implicated in the onset of cold agglutinin disease.
  • Apply diagnostic criteria to facilitate an accurate and timely diagnosis of cold agglutinin disease.
  • Identify complement-mediated therapies for the treatment of cold agglutinin disease based on current and emerging evidence.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Alexander Röth, MD
Alexander Röth, MD
Department of Hematology and
Stem Cell Transplantation
West German Cancer Center
University Hospital Essen
University Duisburg-Essen
Essen, Germany

Disclosures: Grant Research Support: Hoffmann-La Roche; Consultant: Alexion Pharmaceuticals, Apellis Pharmaceuticals, BioCryst Pharmaceuticals, Novartis Pharmaceuticals Corporation, Hoffmann-La Roche, Sanofi.

Sigbjørn Berentsen, MD, PhD
Sigbjørn Berentsen, MD, PhD
Consultant Hematologist and Senior Researcher
Department of Research and Innovation
Helse Fonna HF, Haugesund Hospital
Haugesund, Norway

Disclosures: Consultant: Apellis Pharmaceuticals, Bioverativ (a Sanofi Genzyme company), Momenta Pharmaceuticals, Sobi; Other: Lecture honoraria: Apellis Pharmaceuticals, Bioverativ (a Sanofi Genzyme company), Janssen-Cilag.

Wilma Barcellini, MD
Wilma Barcellini, MD
Director, UOS Physiopathology of Anemias
UO Hematology – Granelli Pavilion
IRCCS Ca’ Granda Foundation
Maggiore Policlinico Hospital
Milan, Italy

Disclosures: Consultant: Apellis Pharmaceuticals, Incyte Corporation, Sanofi.

Catherine M. Broome, MD
Catherine M. Broome, MD
Associate Professor of Medicine
MedStar Georgetown University Hospital’s Lombardi Comprehensive Cancer Center
Washington, DC

Disclosures: Other: Apellis Pharmaceuticals Advisory Board.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By